Developmental toxicity of metal chelating agents

Reproductive Toxicology

Volumn 12, Issue 5, 1998, Pages 499-510

  Domingo, Jose L ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b Lab of Toxicol and Environ Health School of Medicine   (Spain)

Author keywords

Chelating agents; Embryotoxicity; Fetotoxicity; Maternal toxicity; Mineral supplements; Teratogenicity

Indexed keywords

AMINO ACID; CHELATING AGENT; METAL; METAL CHELATE; PHENOL DERIVATIVE; THIOL DERIVATIVE;

ANIMAL; CHELATION THERAPY; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG EFFECT; EMBRYOTOXICITY; ENVIRONMENTAL EXPOSURE; FEMALE; FETOTOXICITY; FETUS DEVELOPMENT; HUMAN; NONHUMAN; PREGNANCY; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; AMINO ACIDS; ANIMALS; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; METALS; PHENOLS; PREGNANCY; SULFHYDRYL COMPOUNDS;

EID: 0032172929     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(98)00036-7     Document Type: Review

References (118)

1. Brewer J, Yuzbasiyan-Gurkan V. Wilson disease. Medicine. 1992;71:139-64.
2. Walshe JM. Treatment of Wilson's disease: the historical background. Q J Med. 1996;89:553-5.
3. Nielsen P, Fischer R, Engelhardt R, Tondüry P, Gabbe EE, Janka GE. Liver iron stores in patients with secondary hemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br J Hematol. 1995;91:827-33.
4. De Sanctis, Pinamonti A, Di Palma A, et al. Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr. 1996;155:368-72.
5. Platen TP, Alfrey AC, Birchall JD, Savory J, Yokel RA. Status and future concerns of clinical and environmental aluminum toxicology. J Toxicol Environ Health. 1996;48:527-41.
6. Yokel RA, Ackrill P, Burgess E, Day JP, Domingo JL, Platen TP, Savory J. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. J Toxicol Environ Health. 1996;48:667-83.
7. Domingo JL. Metal-induced developmental toxicity in mammals: A review. J Toxicol Environ Health. 1994;42:123-41.
8. Domingo JL. Prevention by chelating agents of metal-induced developmental toxicity. Reprod Toxicol. 1995;9:105-13.
9. Golub MS. Maternal toxicity and the identification of inorganic arsenic as a developmental toxicant. Reprod Toxicol. 1995;9: 105-13.
10. Ernhart CB. A critical review of low-level prenatal lead exposure in the human: 1. Effects on the fetus and newborn. Reprod Toxicol. 1992;6:9-19.
11. Ernhart CB. A critical review of low-level prenatal lead exposure in the human: 2. Effects on the developing child. Reprod Toxicol. 1992;6:21-40.
12. Kosnett MJ. Unanswered questions in metal chelation. Clin Toxicol. 1992;30:529-47.
13. Jones MM, Pratt TH. Therapeutic chelating agents. J Chem Educ. 1976;53:342-7.
14. Jones MM. New developments in therapeutic chelating agents as antidotes for metal poisoning. Crit Rev Toxicol. 1991;21:209-33.
15. Jones MM, Basinger MA. A hypothesis for the selection of chelate antidotes for toxic metals. Med Hypotheses. 1982;9:445-53.
16. Jones MM. Antagonists for toxic heavy metals. Proc West Pharmacol Soc. 1984;27:163-7.
17. Mellor DP. Chemistry of chelation and chelating agents. In: Levine WG, ed. The chelation of heavy metals. Oxford: Pergamon Press, 1979:12-7.
18. Chisolm JJ. Jr. BAL, EDTA, DMSA, and DMPS in the treatment of lead poisoning in children. Clin Toxicol. 1992;30:493-504.
19. Aposhian HV. Biologic chelation: 2,3-dimercaptopropanesulfonic acid and meso-dimercaptosuccinic acid. Adv Enz Regul. 1982;20:301-19.
20. Aposhian HV, Aposhian MM. meso-2:3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol. 1990;30:279-306.
21. Llobet JM, Domingo JL, Corbella J. Antidotes for zinc intoxication in mice. Arch Toxicol. 1988;61:321-3.
22. Sanchez DJ, Gomez M, Domingo JL, Llobet JM, Corbella J. Relative efficacy of chelating agents on excretion and tissue distribution of manganese in mice. J Appl Toxicol. 1995;15: 285-8.
23. Stradling GN, Moody JC, Gray SA, Ellender M, Hodgson A. The efficacy of DTPA treatment after deposition of thorium nitrate in the rat lung. Hum Exp Toxicol. 1991;10:15-20.
24. Jones SG, Jones MM. Structure-activity relationships among dithiocarbamate antidotes for acute cadmium chloride intoxication. Environ Health Perspect. 1984;54:285-90.
25. Olivieri NF. Long term therapy with deferiprone. Acta Haematol. 1996;95:37-48.
26. Domingo JL. Adverse effects of aluminum-chelating compounds for clinical use. Adverse Drug React Toxicol Rev. 1996;15:145-65.
27. Peters RA, Stocken LA, Thompson RHS. British anti-Lewisite (BAL). Nature. 1945;156:616-9.
28. Chisolm JJ Jr. Treatment of acute lead intoxication. Choice of chelating agents and supportive therapeutic measures. Clin Toxicol. 1970;3:527-40.
29. Angle CR. Childhood lead poisoning and its treatment. Annu Rev Pharmacol Toxicol. 1993;32:409-34.
30. Gomez M, Sanchez DJ, Colomina MT, Domingo JL, Corbella J. Evaluation of the protective activity of BAL (2,3-dimercaptopropanol) and DMPS (sodium 2,3-dimercaptopropane-1-sulfonate) on methylmercury-induced developmental toxicity in mice. Arch Environ Contam Toxicol. 1994;26:64-8.
31. Hood RD, Pike CT. BAL alleviation of arsenate-induced terato-genesis in mice. Teratology. 1972;6:235-8.
32. Hood RD, Vedel GC. Evaluation of the effect of BAL (2,3-dimercaptopropanol) on arsenite-induced teratogenesis in mice. Toxicol Appl Pharmacol. 1984;73:1-7.
33. Domingo JL, Bosque MA, Llobet JM, Corbella J. Amelioration by BAL (2,3-dimercapto-1-propanol) and DMPS (sodium 2,3-dimercapto-1-propanesulfonic acid) of arsenite developmental toxicity in mice. Ecotoxicol Environ Safety. 1992;23:274-81.
34. Nishimura H, Takagaki S. Developmental anomalies in mice induced by 2,3-dimercaptopropanol (BAL). Anat Rec. 1959;135: 261-7.
35. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995;97:23-38.
36. US Food, and Drug Administration. Succimer approved for severe lead poisoning. FDA Med Bull March. 1991;21:5.
37. Graziano JH, Lolacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr. 1992;120:133-9.
38. Asiedu P, Moulton T, Blum CB, Roldan E, Lolacono NJ, Graziano JH. Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults. Environ Health Perspect. 1995;103:734-9.
39. Domingo JL, Bosque MA, Piera V. meso- 2:3-Dimercaptosuccinic acid and prevention of arsenite embryotoxicity and terato-genicity in the mouse. Fundam Appl Toxicol. 1991;17:314-20.
40. Bosque MA, Domingo JL, Llobet JM, Corbella J. Effects of meso-2,3-dimercaptosuccinic acid (DMSA) on the teratogenicity of sodium arsenate in mice. Bull Environ Contam Toxicol. 1991;47:682-8.
41. Sanchez DJ, Gomez M, Llobet JM, Domingo JL. Effects of meso-2,3-dimercaptosuccinic acid (DMSA) on methyl mercury-induced teratogenesis in mice. Ecotoxicol Environ Safety. 1993; 26:33-9.
42. Domingo JL, Paternain JL, Llobet JM, Corbella J. Developmental toxicity of subcutaneously meso-2,3-dimercaptosuccinic acid in mice. Fundam Appl Toxicol. 1988;11:715-22.
43. Domingo JL, Ortega A, Paternain JL, Llobet JM, Corbella J. Oral meso-2,3-dimercaptosuccinic acid in pregnant Sprague - Dawley rats: Teratogenicity and alterations in mineral metabolism. I. Teratological evaluation. J Toxicol Environ Health. 1990;30: 181-90.
44. Paternain JL, Ortega A, Domingo JL, Llobet JM, Corbella J. Oral meso-2,3-dimercaptosuccinic acid in pregnant Sprague-Dawley rats: Teratogenicity and alterations in mineral metabolism. II. Effect on mineral metabolism. J Toxicol Environ Health. 1990; 30:191-7.
45. Taubeneck MW, Domingo JL, Llobet JM, Keen CL. meso-2,3-Dimercaptosuccinic acid (DMSA) affects maternal and fetal copper metabolism in Swiss mice. Toxicology. 1992;72:27-40.
46. Domingo JL, Bosque MA, Corbella J. Effects of oral meso-2,3-dimercaptosuccinic acid (DMSA) administration on late gestation and postnatal development in the mouse. Life Sci. 1990;47:1745-50.
47. Jones MM, Singh PK, Gale GR, Smith AB, Atkins LM. Cadmium mobilization in vivo by intraperitoneal or oral administration of monoalkyl esters of meso-2,3-dimercaptosuccinic acid in the mouse. Pharmacol Toxicol. 1992;70:336-43.
48. Gale GR, Smith AB, Jones MM, Singh PK. meso- 2,3-Dimercaptosuccinic acid monoalkyl esters: Effect on mercury levels in mice. Toxicology. 1993;81:49-56.
49. Walker EM, Stone A, Milligan LB, et al. Mobilization of lead in mice by administration of monoalkyl esters of meso-2,3-dimercaptosuccinic acid. Toxicology. 1992;76:79-87.
50. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Jones MM, Singh PK. Effects of monoisoamyl meso-2,3-dimercaptosuccinate on arsenite-induced maternal and developmental toxicity in mice. Res Commun Chem Pathol Pharmacol. 1995;89:389-400.
51. Bellés M, Sanchez DJ, Gomez M, Domingo JL, Jones MM, Singh PK. Assessment of the protective activity of monoisoamyl meso-2,3-dimercaptosuccinate against methylmercury-induced maternal and embryo/fetal toxicity in mice. Toxicology. 1996;106: 93-7.
52. 2 retention in rats: 1. Chelation during pregnancy. J Trace Elem Exp Med. 1997;10:173-81.
53. 2 retention in rats: 2. Chelation therapy during lactation. J Trace Elem Exp Med. 1997;10:183-90.
54. Bosque MA, Domingo JL, Corbella J, Jones MM, Singh PK. Developmental toxicity evaluation of monoisoamyl meso-2,3-dimercaptosuccinate in mice. J Toxicol Environ Health. 1994;42: 443-50.
55. Aposhian MM, Maiorino RM, Xu Z, Aposhian HV. Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rats. Toxicology. 1996;109:49-55.
56. Aposhian HV, Bruce DC, Alter W, Dart RC, Hurbult KM Aposhian MM. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with dental amalgam score. FASEB J. 1992;6:2472-6.
57. Aposhian HV, Maiorino RM, Rivera M, et al. Human studies with the chelating agents DMPS and DMSA. Clin Toxicol. 1992;30: 505-28.
58. Planas-Bohne F, Gabard B, Schärfer EH. Toxicological studies on sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Arzneim Forsch/Drug Res. 1980;30:1291-4.
59. Bosque MA, Domingo JL, Paternain JL, Llobet JM, Corbella J. Evaluation of the developmental toxicity of 2,3-dimercapto-1-propanesulfonate (DMPS) in mice. Effect on mineral metabolism. Toxicology. 1990;62:311-20.
60. Domingo JL, Ortega A, Bosque MA, Corbella J. Evaluation of the developmental effects on mice after prenatal, or pre- and postnatal exposure to 2,3-dimercapto-1-propanesulfonic acid (DMPS). Life Sci. 1990;46:1287-92.
61. Llobet JM, Domingo JL, Corbella J. Comparative effects of repeated parenteral administration of several chelators on the distribution and excretion of cobalt. Res Commun Chem Pathol Pharmacol. 1988;60:225-33.
62. McClain RM, Siekierka JJ. The effects of various chelating agents on the teratogenicity of lead nitrate in rats. Toxicol Appl Pharmacol. 1975;31:434-42.
63. Tuchman-Duplessis H, Mercier-Parot L. Influence d'un corps de chelation, l'acide éthylenediaminetétraacétique sur la gestation et le dévelopement foetal du rat. C R Acad Sci Paris. 1956;243: 1064-6.
64. Swenerton H, Hurley LS. Teratogenic effects of a chelating agent and their prevention by zinc. Science. 1971;173:62-4.
65. Apgar J. Use of EDTA to produce zinc deficiency in the pregnant rat. J Nutr. 1977;107:539-45.
66. Hurley LS, Swenerton H. Congenital malformations resulting from zinc deficiency in rats. Proc Soc Exp Biol Med. 1966;123: 692-6.
67. Hurley LS. Zinc deficiency in the developing rat. Am J Clin Nutr. 1969;22:1332-9.
68. Rogers JM, Keen CL, Hurley LS. Zinc deficiency in pregnant Long-Evans hooded rats: teratogenicity and tissue trace elements. Teratology. 1985;31:89-100.
69. Kimmel CA, Sloan CS. Studies on the mechanism of EDTA teratogenesis. Teratology. 1975;12:330-1.
70. Kimmel CA. Effect of route of administration on the toxicity of EDTA in the rat. Toxicol Appl Pharmacol. 1977;40:299-306.
71. Shardein JL, Sakowski R, Petrere J, Humphrey RR. Teratogenesis studies with EDTA and its salts in rats. Toxicol Appl Pharmacol. 1981;61:423-8.
72. Angle CR, McIntire MS. Lead poisoning during pregnancy. Am J Dis Child. 1964;108:436-9.
73. Timpo AE, Amin JS, Casalino MB, Yuceoglu AM. Congenital lead intoxication. J Pediatr. 1979;94:765-7.
74. Llobet JM, Domingo JL, Paternain JL, Corbella J. Treatment of acute lead intoxication. A quantitative comparison of a number of chelating agents. Arch Environ Contam Toxicol. 1990;19:185-9.
75. Ortega A, Gomez M, Domingo JL, Corbella J. The removal of strontium from the mouse by chelating agents. Arch Environ Contam Toxicol. 1989;18:612-6.
76. Llobet JM, Colomina MT, Domingo JL, Corbella J. Influence of several antidotal treatments on the distribution and excretion of strontium. J Environ Sei Health. 1992;A27:1103-14.
77. Sanchez DJ, Colomina MT, Domingo JL, Llobet JM, Corbella J. Developmental toxicity of cyclohexanediaminetetraacetic acid (CDTA) in mice. Res Commun Chem Pathol Pharmacol. 1994; 83:329-40.
78. Colomina MT, Sanchez DJ, Domingo JL, Llobet JM, Corbella J. Effect of the chelator cyclohexanediaminetetraacetic acid (CDTA) on mineral metabolism in pregnant mice. In: Collery P, Poirier LA, Littlefield NA, Etienne JC, eds. Metal ions in biology and medicine. Paris: John Libbey Eurotext, 1994:454-9.
79. Llobet JM, Domingo JL, Corbella J. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion and distribution of cobalt. Arch Toxicol. 1986;58:278-81.
80. Fisher DR, Calder SE, Mays CM, Taylor GN. Ca-DTPA-induced fetal death and malformation in mice. Teratology. 1976;14: 123-8.
81. Gabard B. The influence of DTPA on the synthesis of DNA, RNA, and proteins in the regenerating rat liver. Biochem Pharmacol. 1974;23:901-9.
82. Brummett ES, Mays CW. Teratological studies of Zn-DTPA in mice. Health Phys. 1977;33:624-6.
83. Mays CM, Taylor GN, Fisher DR. Estimated toxicity of CaDTPA to the human fetus. Health Phys. 1979;30:247-9.
84. Fisher DR, Mays CM, Taylor GN. Ca-DTPA toxicity in the mouse fetuses. Health Phys. 1975;29:780-2.
85. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487-95.
86. Tankanow RM. Pathophysiology and treatment of Wilson's disease. Clin Pharm. 1991;10:839-49.
87. Mjolnerod OK, Rasmussen K, Dommerud SA, Gjeruldsen ST. Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet. 1971;1:673-5.
88. Solomon L, Abrams G, Dinner M, Berman L. Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N Engl J Med. 1977;296:54-5.
89. Linares A, Zarranz JJ, Rodriguez-Alarcon J, Diaz-Perez JL. Reversible cutis laxa due to maternal D-penicillamine treatment. Lancet. 1979;2:43.
90. Hartard C, Kunze K. Pregnancy in a patient with Wilson's disease treated with D-penicillamine and zinc sulfate. A case report and review of the literature. Eur Neurol. 1994;34:337-40.
91. Rosa FW. Teratogen update: Penicillamine. Teratology. 1986;33: 127-31.
92. Keen CL, Lönnerdal B, Hurley LS. Teratogenic effects of copper deficiency and excess. In: Sorenson JRJ, ed. Inflammatory diseases and copper. Clifton, NJ: The Humana Press, 1982:109-21.
93. Keen CL, Mark-Savage P, Lönnerdal B, Hurley LS. Teratogenesis and low copper status resulting from D-penicillamine in rats. Teratology. 1982;26:163-5.
94. Keen CL, Mark-Savage P, Lönnerdal B, Hurley LS. Teratogenic effects of D-penicillamine in rats: relation to copper deficiency. Drug-Nutrient Interact. 1983;2:17-34.
95. Mark-Savage P, Keen CL, Hurley LS. Reduction of copper supplementation of teratogenic effects of D-penicillamine. J Nutr. 1983;113:501-10.
96. Scheinberg IH, Sternlieb I. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med. 1975;293:1330-2.
97. Marecek Z, Graf M. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med. 1976;295:841-2.
98. Banner W Jr, Koch M, Capin DM, Hopf SB, Chang S, Tong TD. Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds. Toxicol Appl Pharmacol. 1986;83:142-7.
99. Ottenwalder H, Simon P. Differential effect of N-acetylcysteine on excretion of the metals Hg, Cd, Pb and Au. Arch Toxicol. 1987;60:401-2.
100. Endo A, Watanabe T. Analysis of protective activity of N-acetylcysteine against teratogenicity of heavy metals. Reprod Toxicol. 1988;2:141-4.
101. Ornaghi F, Ferrini S, Prati M, Giavini E. The protective effects of N-acetyl-L-cysteine against methyl mercury embryotoxicity in mice. Fund Appl Toxicol. 1993;20:437-45.
102. Fujimoto T, Fuyuta M, Kiyofuji E, Hirata S. Prevention by tiopronin (2-mercaptopropionyl glycine) of methylmercuric chloride-induced teratogenic and fetotoxic effects in mice. Teratology. 1979;20:297-302.
103. Domingo JL, Bosque MA, Luna M, Corbella J. Prevention by Tiron (sodium 4,5-dihydroxybenzene-1,3-disulfonate) of vanadate-induced developmental toxicity in mice. Teratology. 1993; 48:133-8.
104. Bosque MA, Domingo JL, Llobet JM, Corbella J. Effectiveness of sodium 4,5-dihydroxybenzene-1,3-disulfonate (Tiron) in protecting against uranium-induced developmental toxicity in mice. Toxicology. 1993;79:149-56.
105. Ortega A, Sanchez DJ, Domingo JL, Llobet JM, Corbella J. Developmental toxicity evaluation of Tiron (sodium 4,5-dihydroxybenzene-1,3-disulfonate) in mice. Res Commun Chem Pathol Pharmacol. 1991;73:97-106.
106. Blanc P, Hryhorczuk D, Danel I. Deferoxamine treatment of acute iron intoxication in pregnancy. Obstet Gynecol. 1984;64: 12S-14S.
107. Thomas RM, Skalicka AE. Succesful pregnancy in transfusion-dependent thalassaemia. Arch Dis Child. 1980;55:572-4.
108. Martin K. Succesful pregnancy in β-thalassaemia major. Aust Paediatr J. 1983;19:182-3.
109. Christiaens GC, Rijksen G, Marx J, Pott-Hofstede D, Staal GE. Desferrioxamine in pregnancy. Arch Gynecol Obstet. 1985; 237(suppl):80.
110. Olenmark M, Biber B, Dottori O. Fatal iron intoxication in late pregnancy. Clin Toxicol. 1987;25:347-59.
111. McElhatton PR, Roberts JC, Sullivan FM. The consequences of iron overdose and its treatment with desferrioxamine in pregnancy. Hum Exp Toxicol. 1991;10:251-9.
112. Lacoste H, Goyert GL, Goldman LS, Wright DJ, Schwartz DB. Acute iron intoxication in pregnancy: case report and review of the literature. Obstet Gynecol. 1992;80:500-1.
113. Bosque MA, Domingo JL, Corbella J. Assessment of the developmental toxicity of deferoxamine in mice. Arch Toxicol. 1995; 69:467-71.
114. Tenenbein M. Poisoning in pregnancy. In Koren G, ed. Maternal-fetal toxicology: a clinical guide. New York: Marcel Dekker, 1990:699-701.
115. Schnebli HP. Preclinical evaluation of CGP 37 391 (L1). Biology Report ERS 62/93. Ciba-Geigy Ltd, Basle, July. 1993.
116. Tanaka H, Inomata K, Arima M. Teratogenic effects of triethylene tetramine dihydrochloride on the mouse brain. J Nutr Sci Vitaminol. 1993;39:177-88.
117. Walshe JM. The management of pregnancy in Wilson's disease treated with trientine. Q J Med. 1986;225:81-7.
118. Taubeneck MW, Daston GP, Rogers JM, Keen CL. Altered maternal zinc metabolism following exposure to diverse developmental toxicants. Reprod Toxicol. 1994;8:25-40.